UA Expertise on Valley Fever (Coccidioidomycosis)
Valley fever, also known as coccidioidomycosis or cocci, is primarily a lung disease that is common in the Southwest United States and northwestern Mexico. It is caused by the fungus Coccidioides, which grows in soils in areas with low rainfall, high summer temperatures and moderate winter temperatures. The fungal spores become airborne when the soil is disturbed by winds, construction, farming and other activities.
Valley fever is more likely to occur during certain seasons. In Arizona, the highest prevalence of infections occurs from June through July and from October through November. In California, the risk of infection is highest from June through November.
In susceptible people, such as those who are immunocompromised, and animals, infection occurs when a spore is inhaled. Within the lung, the spore changes into a larger, multicellular structure called a spherule. The spherule grows and bursts, releasing endospores, which, in turn, develop into spherules. Symptoms of Valley fever generally occur within three weeks of exposure. It is not a contagious disease – meaning it is not passed from person to person. Related infections are rare.
Many domestic and native animals are susceptible to the disease, including dogs, cats, horses, cattle, sheep, burros, coyotes, rodents, bats and snakes.
University of Arizona Valley Fever Center for Excellence
The Arizona Board of Regents established the UA Valley Fever Center for Excellence in 1996 for the benefit of the entire state. Based at the UA Health Sciences campus—which includes the UA College of Medicine – Tucson, College of Pharmacy, College of Nursing and Mel and Enid Zuckerman College of Public Health—the center has developed a research base that includes the state’s three universities, and an information program for the scientific community and the general public. Its work encompasses public awareness, clinical guidelines and training, and research into rapid detection methods for the disease as well as development of a vaccine for both animals and humans. Much of the center’s research is conducted at the UA BIO5 Institute.
The Valley Fever Center for Excellence was recently awarded a four-year, $4.8 million grant for research to speed development of a vaccine to combat Valley fever, the sometimes deadly respiratory illness caused by Coccidioides spores found in soils of the U.S. Southwest. The center will use the money to accelerate development of a Valley fever vaccine for dogs that one day may lead to a successful human vaccine. A California-based biotech company and Colorado State University have joined the center in the effort.
Valley Fever in People
Valley fever derives its name from its discovery in the San Joaquin Valley of California, where it was also referred to as "San Joaquin Valley Fever" or "Desert Rheumatism."
The medical name for Valley fever is coccidioidomycosis (often shortened to "cocci" caused by the fungus Coccidioides spp. (C. immitis, C. posadasii).
It is not contagious. For most, symptoms — if any — are mild, including fatigue, fever, headaches, rash, night sweats, weight loss, joint or muscle aches. For some people, the disease may spread to the skin, joints, bone or, in the most severe cases, the brain.
The disease usually affects the lungs and can cause pneumonia.
It is found in the southern deserts of Arizona (including Maricopa, Pima and Pinal counties), the central valley and southern portions of California (including Fresno, Kern, and Kings counties), the southern tip of Nevada, southern Utah, southern New Mexico, western Texas (especially along the Rio Grande), and the northern and Pacific coastal areas of Mexico. Recently, a pocket of Coccidioides has been identified in Washington. Some areas have been identified in Central and South America as well.
For more information, visit http://vfce.arizona.edu/valley-fever-people
Valley Fever in Dogs
Because of their susceptibility and popularity as human companions, dogs comprise the majority of animal cases of Valley fever. Owners spend hundreds to thousands of dollars each year, especially in Arizona, diagnosing, treating, and following up care for their dogs with Valley fever. It is estimated that Valley fever costs all Arizona dog owners at least $60 million per year.
For more information, visit http://vfce.arizona.edu/valley-fever-dogs
University of Arizona Experts on Valley Fever
John Galgiani, M.D.
Professor of Medicine, Division of Infectious Diseases, Department of Medicine, UA College of Medicine – Tucson
Director, UA Valley Fever Center for Excellence
Member, UA BIO5 Institute
Dr. Galgiani has been working with Valley fever (Coccidioidomycosis) for three decades. As center founder and director his passion is research in the treatment of Valley fever. This involves studies to improve detection of the fungus in the environment, to increase the sensitivity of diagnostic tests for patients, and to develop a vaccine to prevent the disease in both humans and animals. He also has served as lead author for the Infectious Diseases Society of America “Clinical Practice Guideline for the Treatment of Coccidioidomycosis” in 2005 and 2016. He sees patients at the Valley Fever Clinic at Banner – University Medical Center Tucson.Website
Fariba M. Donovan, M.D.
Assistant Professor of Medicine, Division of Infectious Diseases, Department of Medicine, UA College of Medicine – Tucson
Research Investigator, UA Valley Fever Center for Excellence
As both a practicing physician and a research scientist, Dr. Donovan has long cultivated a particular interest in medical mycology. Her research focuses on the identification of virulence factors and interaction of several fungi with human hosts. Her goal is to identify and characterize regulatory mechanisms at a post-transcriptional level that have a crucial role in development of Valley fever in humans.Website
Yves Lussier, M.D.
Professor of Medicine and Statistics Graduate Interdisciplinary Program, UA College of Medicine – Tucson
Associate Director, Bioinformatics, UA BIO5 Institute
Director, Center for Biomedical Informatics and Biostatistics
Associate Vice President for Health Sciences and Chief Knowledge Officer, UA Health Sciences
Dr. Lussier a professional engineer and physician-scientist is an international expert in translational bioinformatics and a pioneer in research informatics techniques including systems biology, data representation through ontologies and high-throughput methods in personalized medicine. As such, he is co-investigator on an NIH/NIAID funded study to examine immunogenetic underpinnings of Valley fever respiratory infectionsWebsite
Professor of Immunobiology, Department of Immunobiology, UA College of Medicine – Tucson
Member, UA Cancer Center
Member, UA Center on Aging
The Frelinger Lab has been interested for some years in immune responses to the lung pathogens, influenza virus and Francisella tularensis. At the UA, it has begun collaborations on the role of T cell responses in Coccidioides infections and development of an effective vaccine.
Kenneth Knox, M.D.
Associate Dean, Faculty Affairs and Development, UA College of Medicine – Phoenix
Member, UAHS Asthma and Airway Diseases Research Center
Member, UA BIO5 Institute
Part of Dr. Knox’s research has been focused on various clinical and translational projects dealing with coccidioidomycosis including use of bronchoalveolar lavage to study lung mucosal responses to Coccidioides. A co-principal investigator for a clinical trial to test Valley fever rapid detection methods in Arizona through an NIH grant to Duke University Human Vaccine Institute, he has also been working on examination of radiographic manifestations of coccidioidomycosis and how antifungal prophylaxis affects lung transplant recipients.
Dominick Sudano, M.D.
Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, UA College of Medicine – Tucson
Dr. Sudano’s research findings, “Management of Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease,” look at the impact of Valley fever on patients also taking biologics used in treating some forms of arthritis. The study suggests it may be safe to continue treatment in patients with asymptomatic coccidioidomycosis (Valley fever). He sees patients at the Rheumatology Physician Offices and Infusion Clinic at Banner – UMC South.
Lisa Shubitz, D.V.M.
Research Scientist, UA Valley Fever Center for Excellence
A veterinarian and leading expert on Valley fever in animals, Dr. Shubitz has focused her research on developing a vaccine for Valley fever, studying the epidemiology of the disease in canines, the ecological distribution of the fungus in Southern Arizona, and interactions between the host (both animal and human) and the fungus that causes Valley fever using animal models.
Professor of Climatology, School of Geography and Development, UA College of Social and Behavioral Sciences
Comrie has been studying climatic impacts on the spread of coccidioidomycosis in the desert of Southern Arizona. His other interests include regional and local climate variability, air quality, climate-health relationships, mapping, spatial modeling and interpolation and the effects of climate change on human health.
Professor, Department of Pharmacy Practice and Science, UA College of Pharmacy
Nix has played a key role in design and implementation of the Nikkomycin Z clinical trials at the UA Valley Fever Center for Excellence. He teaches infectious disease topics in multiple courses and precepts students and residents on related rotations. His other research interests include treatment of bacterial infections, antibacterial resistance and antimicrobial stewardship.
Professor of Plant Pathology and Microbiology, School of Plant Sciences, UA College of Agriculture and Life Sciences
Director, Keating Select Agent BSL3 Laboratory
Orbach’s focus is studying the ecological niche of the fungus that causes Valley fever and analysis of global gene expression in Coccidioides posadasii during both saprobic and parasitic growth. In his analysis, he has been using a technique called serial analysis of gene expression to produce an RNA snapshot of the fungal spores. His research interests also include molecular genetics of fungal pathogenicity in animals and plants. He also is involved in animal testing of a vaccine for Valley fever, for which a breakthrough article was published in August 2016 by the journal Infection and Immunity.
UA Valley Fever Experts in the News
U.S. Centers for Disease Control and Prevention